Meta-analysis of efficacy and safety of rituximab for children with refractory nephrotic syndrome based on the real world

REN Xiangge; YU Xin; ZHANG Jiawei; ZHAO Peidong; ZHAI Wensheng

doi:10.6039/j.issn.1001-0408.2024.21.16

您当前的位置：

首页 >

文章列表页 >

Meta-analysis of efficacy and safety of rituximab for children with refractory nephrotic syndrome based on the real world

更新时间：2024-11-08

- Meta-analysis of efficacy and safety of rituximab for children with refractory nephrotic syndrome based on the real world
- ZHONGGUO YAOFANG Vol. 35, Issue 21, Pages: 2668-2675(2024)
- 作者机构：
  
  1.河南中医药大学第一附属医院儿科医院，郑州　450014
  2.河南中医药大学儿科医学院，郑州　450046
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2024.21.16
  CLC： R969.3;R726.9
- Published：15 November 2024，
  
  Received：16 April 2024，
  
  Revised：27 September 2024，
- 稿件说明：
移动端阅览
任相阁,禹欣,张佳伟等.真实世界中利妥昔单抗治疗儿童难治性肾病综合征的有效性与安全性的Meta分析 ^Δ[J].中国药房,2024,35(21):2668-2675.

REN Xiangge,YU Xin,ZHANG Jiawei,et al.Meta-analysis of efficacy and safety of rituximab for children with refractory nephrotic syndrome based on the real world[J].ZHONGGUO YAOFANG,2024,35(21):2668-2675.
任相阁,禹欣,张佳伟等.真实世界中利妥昔单抗治疗儿童难治性肾病综合征的有效性与安全性的Meta分析 ^Δ[J].中国药房,2024,35(21):2668-2675. DOI： 10.6039/j.issn.1001-0408.2024.21.16.

REN Xiangge,YU Xin,ZHANG Jiawei,et al.Meta-analysis of efficacy and safety of rituximab for children with refractory nephrotic syndrome based on the real world[J].ZHONGGUO YAOFANG,2024,35(21):2668-2675. DOI： 10.6039/j.issn.1001-0408.2024.21.16.

摘要

目的

评价利妥昔单抗（RTX）在真实世界中治疗儿童难治性肾病综合征（RNS）的有效性和安全性。

方法

系统检索中国知网、万方、维普、PubMed、Embase、Web of Science、the Cochrane Library以及CINAHL数据库，筛选文献、评价质量并提取资料后，使用R 4.2.2和RStudio软件对提取的文献数据进行Meta分析。使用逐一剔除法进行敏感性分析来评估合并结果的稳健性。绘制漏斗图和Egger检验检测纳入文献是否存在发表偏倚。

结果

本研究共纳入26篇真实世界研究，涉及激素依赖型肾病综合征/频繁复发型肾病综合征（SDNS/FRNS）患儿996例，激素耐药型肾病综合征（SRNS）患儿205例。Meta分析结果表明，RTX治疗RNS的完全缓解（CR）率为46%（95%CI为37%～56%）、部分缓解（PR）率为22%（95%CI为14%～31%）、停药率为35%（95%CI为25%～44%）。亚组分析结果显示，RTX治疗SDNS/FRNS患儿的CR率为49%（95%CI为37%～62%）、PR率为25%（95%CI为0～50%）、停药率为41%（95%CI为29%～52%），治疗SRNS患儿的CR率为42%（95%CI为27%～56%）、PR率为22%（95%CI为12%～32%）、停药率为21%（95%CI为4%～38%）。使用RTX治疗SDNS/FRNS患儿1年及以内的复发率为39%（95%CI为21%～57%），2年及以上的复发率为18%（95%CI为18%～98%）。安全性方面，不良反应以轻微输液反应为主，发生率为13%（95%CI为8%～22%）。敏感性分析提示本研究结果稳健。轻微输液反应发生率存在发表偏倚。

结论

RTX治疗儿童RNS有效且安全。

Abstract

OBJECTIVE

To evaluate the efficacy and safety of rituximab （RTX） in the treatment of children with refractory nephrotic syndrome （RNS） based on the real world by meta-analysis.

METHODS

A systematic search was conducted on CNKI， Wanfang， VIP， PubMed， Embase， Web of Science， the Cochrane Library， and CINAHL databases to strictly screen the literature and evaluate their quality. A meta-analysis was performed on the extracted literature data using R 4.2.2 and RStudio software.

RESULTS

A total of 26 real-world studies were included in this study， involving 996 children with steroid-dependent nephrotic syndrome/frequente-relapse nephrotic syndrome （SDNS/FRNS） and 205 children with steroid-resistant nephrotic syndrome （SRNS）. The results of the meta-analysis showed that the complete remission （CR） rate of RTX treatment for RNS was 46% （95%CI： 37%-56%）， the partial remission （PR） rate was 22% （95%CI： 14%-31%）， and the discontinuation rate was 35% （95%CI： 25%-44%）. The results of subgroup analysis showed that the CR rate of RTX treatment in SDNS/FRNS children was 49% （95%CI： 37%-62%）， PR rate was 25% （95%CI： 0-50%）， discontinuation rate was 41% （95%CI： 29%-52%）； the CR rate in SRNS children was 42% （95%CI： 27%-56%）， PR rate was 22%（95%CI： 12%-32%）， discontinuation rate was 21% （95%CI： 4%-38%）. The recurrence rate in children with SDNS/FRNS was 39% （95%CI： 21%-57%） within 1 year or less， 18% （95%CI： 18%-98%） in 2 years and more. As for safety， the majority of adverse reactions were mild infusion reactions， with an incidence of 13% （95%CI： 8%-22%）. Sensitivity analysis suggested that the results were robust. There was publication bias in mild infusion reaction rate.

CONCLUSIONS

RTX is effective and safe in the treatment of RNS in children.

关键词

难治性肾病综合征频繁复发激素依赖激素耐药真实世界儿童

Keywords

frequente-relapsesteroid-dependentsteroid-resistantreal worldchildren

references

VIVARELLI M，GIBSON K，SINHA A，et al. Childhood nephrotic syndrome[J]. Lancet，2023，402（10404）：809-824.

NOONE D G，IIJIMA K，PAREKH R. Idiopathic nephrotic syndrome in children[J]. Lancet，2018，392（10141）：61-74.

TRAUTMANN A，VIVARELLI M，SAMUEL S，et al. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome[J]. Pediatr Nephrol，2020，35（8）：1529-1561.

利妥昔单抗在儿童激素敏感型肾病综合征中应用临床实践指南工作组. 利妥昔单抗在儿童激素敏感型肾病综合征中应用临床实践指南[J]. 中国循证儿科杂志，2023，18（4）：245-254.

Clinical Practice Guidelines Working Group for the Application of Rituximab in Children with Hormone Sensitive Nephrotic Syndrome. Clinical practice guidelines for the application of rituximab in children with hormone sensitive nephrotic syndrome[J]. Chin J Evid Based Pediatr，2023，18（4）：245-254.

GBADEGESIN R A，WINN M P，SMOYER W E. Genetic testing in nephrotic syndrome：challenges and opportunities[J]. Nat Rev Nephrol，2013，9（3）：179-184.

倪锦玉，张蒙蒙，任相阁，等. 中药联合激素非拖尾疗法治疗儿童难治性肾病综合征的临床研究[J]. 南京中医药大学学报，2023，39（7）：669-676.

NI J Y，ZHANG M M，REN X G，et al. Clinical study of traditional Chinese medicine combined with hormone non-tailing therapy in the treatment of children with refractory nephrotic syndrome[J]. J Nanjing Univ Tradit Chin Med，2023，39（7）：669-676.

ZHAO J H，LIU Z H. Treatment of nephrotic syndrome：going beyond immunosuppressive therapy[J]. Pediatr Nephrol，2020，35（4）：569-579.

CHAN E Y H，YAP D Y H，COLUCCI M，et al. Use of rituximab in childhood idiopathic nephrotic syndrome[J]. Clin J Am Soc Nephrol，2023，18（4）：533-548.

IIJIMA K，SAKO M，NOZU K. Rituximab for nephrotic syndrome in children[J]. Clin Exp Nephrol，2017，21（2）：193-202.

KALLASH M，SMOYER W E，MAHAN J D. Rituximab use in the management of childhood nephrotic syndrome[J]. Front Pediatr，2019，7：178.

BASU B，SANDER A，ROY B，et al. Efficacy of rituxi- mab vs. tacrolimus in pediatric corticosteroid-dependent nephrotic syndrome：a randomized clinical trial[J]. JAMA Pediatr，2018，172（8）：757-764.

RAVANI P，MAGNASCO A，EDEFONTI A，et al. Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome：a randomized controlled trial[J]. Clin J Am Soc Nephrol，2011，6（6）：1308-1315.

RAVANI P，LUGANI F，DROVANDI S，et al. Rituximab vs. low-dose mycophenolate mofetil in recurrence of steroid-dependent nephrotic syndrome in children and young adults：a randomized clinical trial[J]. JAMA Pediatr，2021，175（6）：631-632.

NAKAGAWA T，SHIRATORI A，KAWABA Y，et al. Efficacy of rituximab therapy against intractable steroid-resistant nephrotic syndrome[J]. Pediatr Int，2016，58（10）：1003-1008.

SUN L，XU H，SHEN Q，et al. Efficacy of rituximab therapy in children with refractory nephrotic syndrome：a prospective observational study in Shanghai[J]. World J Pediatr，2014，10（1）：59-63.

ZACHWIEJA J，SILSKA-DITTMAR M，ŻUROWSKA A，et al. Multicenter analysis of the efficacy and safety of a non-standard immunosuppressive therapy with rituxi- mab in children with steroid-resistant nephrotic syndrome[J]. Clin Exp Pharmacol Physiol，2019，46（4）：313-321.

MAGNASCO A，RAVANI P，EDEFONTI A，et al. Rituxi- mab in children with resistant idiopathic nephrotic syndrome[J]. J Am Soc Nephrol，2012，23（6）：1117-1124.

张喻，曲艺，董丽，等. 真实世界证据与随机对照试验证据比较研究[J]. 中国新药杂志，2021，30（11）：971-975.

ZHANG Y，QU Y，DONG L，et al. A comparative study of real-world evidence and randomized controlled trial evidence[J]. Chin J N Drugs，2021，30（11）：971-975.

中华医学会儿科学分会肾脏学组. 儿童激素敏感、复发/依赖肾病综合征诊治循证指南：2016[J]. 中华儿科杂志，2017，55（10）：729-734.

Nephrology Group，Pediatric Credits of the Chinese Medical Association. Evidence-based guidelines for diagnosis and treatment of hormone sensitive，recurrent/dependent nephrotic syndrome in children：2016[J]. Chin J Pediatr，2017，55（10）：729-734.

MUNN Z，BARKER T H，MOOLA S，et al. Methodological quality of case series studies：an introduction to the JBI critical appraisal tool[J]. JBI Evid Synth，2020，18（10）：2127-2133.

顾莺，张慧文，周英凤，等. JBI循证卫生保健中心关于不同类型研究的质量评价工具：分析性研究的质量评价[J]. 护士进修杂志，2018，33（5）：400-403.

GU Y，ZHANG H W，ZHOU Y F，et al. The Joanna Briggs Institute critical appraisal tools used in systematic reviews：analytic study[J]. J Nurses Train，2018，33（5）：400-403.

SINHA R，BANERJEE S，MUKHERJEE A，et al. Early use of rituximab in calcineurin inhibitor-refractory and steroid-resistant nephrotic syndrome[J]. Kidney Int Rep，2020，5（12）：2354-2357.

BASU B，MAHAPATRA T K S，MONDAL N. Mycophenolate mofetil following rituximab in children with steroid-resistant nephrotic syndrome[J]. Pediatrics，2015，136（1）：e132-e139.

KAMEI K，OKADA M，SATO M，et al. Rituximab treatment combined with methylprednisolone pulse therapy and immunosuppressants for childhood steroid-resistant nephrotic syndrome[J]. Pediatr Nephrol，2014，29（7）：1181-1187.

白玲，陆晨. 利妥昔单抗治疗儿童特发性膜性肾病的疗效分析[J].世界最新医学信息文摘，2020，20（91）：1-2，5.

BAI L，LU C.Efficacy analysis of rituximab in the treatment of idiopathic membranous nephropathy in children [J]. World Lat Med Informat，2020，20 （91）：1-2，5.

王美秋，王忍，夏正坤，等. 利妥昔单抗治疗难治性激素耐药型肾病综合征的疗效和安全性[J]. 中华实用儿科临床杂志，2021，36（5）：355-358.

WANG M Q，WANG R，XIA Z K，et al. Efficacy and safety of rituximab in the treatment of refractory steroid-resistant nephrotic syndrome[J]. Chin J Appl Clin Pediatr，2021，36（5）：355-358.

AL SALLOUM A A，AL HERBISH A J，AL HISSI M A，et al. The outcome of rituximab in treating steroid dependent nephrotic syndrome.：histopathology and immunosuppressive drugs as predicting factors[J]. Saudi Med J，2022，43（7）：760-764.

SELLIER-LECLERC A L，BAUDOUIN V，KWON T， et al. Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood：follow-up after CD19 recovery[J]. Nephrol Dial Transplant，2012，27（3）：1083-1089.

CHAN E Y，WEBB H，YU E，et al. Both the rituximab dose and maintenance immunosuppression in steroid-dependent/frequently-relapsing nephrotic syndrome have important effects on outcomes[J]. Kidney Int，2020，97（2）：393-401.

CHAN C Y，TEO S，LU L J，et al. Low regulatory T-cells：a distinct immunological subgroup in minimal change nephrotic syndrome with early relapse following rituximab therapy[J]. Transl Res，2021，235：48-61.

FUJINAGA S，HIRANO D，NISHIZAKI N，et al. Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine[J]. Pediatr Nephrol，2010，25（3）：539-544.

KIM J H，PARK E，HYUN H S，et al. Long-term repeated rituximab treatment for childhood steroid-dependent nephrotic syndrome[J]. Kidney Res Clin Pract，2017，36（3）：257-263.

RAVANI P，PONTICELLI A，SICILIANO C，et al. Ritu- ximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome[J]. Kidney Int，2013，84（5）：1025-1033.

GOMES R，MOSCA S，BASTOS-GOMES M，et al. Rituximab therapy for childhood onset idiopathic nephrotic syndrome：experience of a Portuguese tertiary center[J]. J Bras Nefrol，2023，45（3）：326-334.

TELLIER S，BROCHARD K，GARNIER A，et al. Long-term outcome of children treated with rituximab for idiopathic nephrotic syndrome[J]. Pediatr Nephrol，2013，28（6）：911-918.

WEBB H，JAUREGUIBERRY G，DUFEK S，et al. Cyclophosphamide and rituximab in frequently relapsing/steroid-dependent nephrotic syndrome[J]. Pediatr Nephrol，2016，31（4）：589-594.

NIU X L，HAO S，WANG P，et al. Single dose of rituxi- mab in children with steroid-dependent minimal change nephrotic syndrome[J]. Biomed Rep，2016，5（2）：237-242.

都娟，黄建萍，王硕，等. 利妥昔单抗在小儿频复发肾病综合征中的应用[J]. 中华实用儿科临床杂志，2014，29（9）：659-662.

DU J，HUANG J P，WANG S，et al. Rituximab in treatment of children with frequently relapsed nephrotic syndrome[J]. Chin J Appl Clin Pediatr，2014，29（9）：659-662.

方香，高春林，夏正坤，等. 利妥昔单抗治疗儿童频繁复发型肾病综合征的远期观察[J]. 中华实用儿科临床杂志，2019，34（5）：352-354.

FANG X，GAO C L，XIA Z K，et al. Long-term observation of rituximab therapy for children with frequently relapsing nephrotic syndrome[J]. Chin J Appl Clin Pediatr，2019，34（5）：352-354.

王道静，王筱雯，丁娟娟，等. 利妥昔单抗在儿童难治性肾病综合征中的疗效评估[J]. 中华实用儿科临床杂志，2022，37（19）：1473-1477.

WANG D J，WANG X W，DING J J，et al. Evaluation of the therapeutic effect of rituximab in children with refractory nephrotic syndrome [J] Chin J Appl Clinic Pediatr，2022，37 （19）：1473-1477.

王汝琼，林道炯，吴守业，等. 利妥昔单抗对激素依赖型肾病综合征患儿T淋巴细胞亚群和尿CD80水平的影响[J]. 东南大学学报（医学版），2021，40（5）：612-617.

WANG R Q，LIN D J，WU S Y，et al. Effects of rituximab on T lymphocyte subsets and urinary CD80 levels in children with steroid-dependent nephrotic syndrome[J]. J Southeast Univ（Med Sci Ed），2021，40（5）：612-617.

TAŞDEMIR M，CANPOLAT N，YILDIZ N，et al. Ritu- ximab treatment for difficult-to-treat nephrotic syndrome in children：a multicenter，retrospective study[J]. Turk J Med Sci，2021，51（4）：1781-1790.

HOSEINI R，SABZIAN K，OTUKESH H，et al. Efficacy and safety of rituximab in children with steroid- and cyclosporine-resistant and steroid- and cyclosporine-dependent nephrotic syndrome[J]. Iran J Kidney Dis，2018，12（1）：27-32.

TOPALOĞLU R，GÜLHAN B，ÇELEGEN K，et al. Rituximab for children with difficult-to-treat nephrotic syndrome：its effects on disease progression and growth[J]. Front Pediatr，2019，7：313.

任静，唐文娟，邵珍珍，等. 68例单次利妥昔单抗治疗儿童原发性肾病综合征激素依赖的护理[J]. 全科护理，2019，17（25）：3149-3151.

REN J，TANG W J，SHAO Z Z，et al. Nursing care of 68 cases of hormone dependence in children with primary nephrotic syndrome treated with single rituximab[J]. Chin Gen Pract Nurs，2019，17（25）：3149-3151.

张涛，沈茜，徐虹，等. 利妥昔单抗治疗儿童原发性难治性肾病综合征疗效及其影响因素的自身前后对照研究[J]. 中国循证儿科杂志，2018，13（3）：161-165.

ZHANG T，SHEN Q，XU H，et al. The effect and multiple-factor analysis of rituximab treatment in children with primary refractory nephrotic syndrome[J]. Chin J Evid Based Pediatr，2018，13（3）：161-165.

WANG C S，GREENBAUM L A. Nephrotic syndrome[J]. Pediatr Clin N Am，2019，66（1）：73-85.

DELBET J D，LECLERC G，ULINSKI T. Idiopathic nephrotic syndrome and rituximab：may we predict circula- ting B lymphocytes recovery?[J]. Pediatr Nephrol，2019，34（3）：529-532.

JELLOULI M，CHARFI R，MAALEJ B，et al. Rituximab in the management of pediatric steroid-resistant nephrotic syndrome：a systematic review[J]. J Pediatr，2018，197：191-197.e1.

XUE C，YANG B，XU J，et al. Efficacy and safety of rituximab in adult frequent-relapsing or steroid-dependent minimal change disease or focal segmental glomerulosclerosis：a systematic review and meta-analysis[J]. Clin Kidney J，2021，14（4）：1042-1054.

HOGAN J，DOSSIER C，KWON T，et al. Effect of diffe- rent rituximab regimens on B cell depletion and time to relapse in children with steroid-dependent nephrotic syndrome[J]. Pediatr Nephrol，2019，34（2）：253-259.

MAXTED A P，DALRYMPLE R A，CHISHOLM D，et al. Low-dose rituximab is no less effective for nephrotic syndrome measured by 12-month outcome[J]. Pediatr Nephrol，2019，34（5）：855-863.

KEMPER M J，ALTROGGE H，GANSCHOW R，et al. Serum levels of immunoglobulins and IgG subclasses in steroid sensitive nephrotic syndrome[J]. Pediatr Nephrol，2002，17（6）：413-417.

KAMEI K，TAKAHASHI M，FUYAMA M，et al. Rituximab-associated agranulocytosis in children with refractory idiopathic nephrotic syndrome：case series and review of literature[J]. Nephrol Dial Transplant，2015，30（1）：91-96.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Difference analysis of ADE signal for irinotecan in adults and children

Effects of ADRB2 gene regulatory region polymorphism on the efficacy of SABA in the treatment of acute asthma attack in children

我院2009－2011 年呼吸道感染患儿5 种常见细菌构成比及耐药性分析

临床药师参与1 例严重创伤患儿的药学监护

头孢丙烯治疗儿童化脓性扁桃体炎的疗效观察

Related Author

ZHU Zengyan

ZHOU Mi

WANG Wenjuan

SHANG Xiang

DU Xiaohuan

LI Fang

ZHANG Shinan

WEI Bing

Related Institution

Dept. of Pharmacy， Children’s Hospital of Soochow University

Dept. of Pharmacy， Suzhou Guangji Hospital

Dept. of Neonatology， General Hospital of Northern Theater Command

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰